Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
MBX Biosciences, Inc. ( (MBX) ) has shared an announcement.
On September 4, 2025, MBX Biosciences announced the dosing of the first participant in a Phase 1 trial of MBX 4291, a prodrug candidate for obesity treatment. This trial aims to evaluate the safety and efficacy of MBX 4291, with topline results expected in 2027. The trial design includes single and multiple ascending doses in various cohorts, potentially positioning MBX 4291 as a best-in-class weight loss treatment with improved tolerability and once-monthly administration.
The most recent analyst rating on (MBX) stock is a Buy with a $36.00 price target. To see the full list of analyst forecasts on MBX Biosciences, Inc. stock, see the MBX Stock Forecast page.
Spark’s Take on MBX Stock
According to Spark, TipRanks’ AI Analyst, MBX is a Underperform.
MBX Biosciences faces significant challenges with its zero revenue and increasing losses, heavily impacting financial performance. Bearish technical indicators and valuation concerns compound the risks. While the strategic board appointment is a positive step, it does not offset the primary financial and operational difficulties.
To see Spark’s full report on MBX stock, click here.
More about MBX Biosciences, Inc.
MBX Biosciences is a clinical-stage biopharmaceutical company based in Carmel, Indiana, focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company is advancing a pipeline of candidates for endocrine and metabolic disorders, including MBX 4291 for obesity, canvuparatide for chronic hypoparathyroidism, and imapextide for post-bariatric hypoglycemia.
Average Trading Volume: 385,330
Technical Sentiment Signal: Strong Buy
Current Market Cap: $489.5M
Learn more about MBX stock on TipRanks’ Stock Analysis page.